Skip to main content

Table 1 Baseline patient demographic and clinical characteristics

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

 

CCRT with cetuximab group (n = 62)

CCRT group (n = 124)

P value

Age, years

  

1

 Mean

46.32 (25–64)

46.05 (28–66)

 

Sex

  

1

 Male

50 (80.6%)

100 (80.6%)

 

 Female

12 (19.4%)

24 (19.4%)

 

Pathological type

  

1

 WHO type II

3 (4.8%)

4 (3.2%)

 

 WHO type III

59 (95.2%)

120 (96.8%)

 

T category

  

1

 T2

14 (22.6%)

28 (22.6%)

 

 T3

41 (66.1%)

82 (66.1%)

 

 T4

7 (11.3%)

14 (11.3%)

 

N category

  

1

 N0

6 (9.7%)

12 (9.7%)

 

 N1

25 (40.3%)

50 (40.3%)

 

 N2

28 (45.2%)

56 (45.2%)

 

 N3

3 (4.8%)

6 (4.8%)

 

Disease stage

  

1

 II

5 (8.1%)

10 (8.1%)

 

 III

47 (75.8%)

94 (75.8%)

 

 IVA

7 (11.3%)

14 (11.3%)

 

 IVB

3 (4.8%)

6 (4.8%)

 

RT technique

  

1

 2DRT

10 (16.1%)

20 (16.1%)

 

 IMRT

52 (83.9%)

104 (83.9%

 

Cisplatin delivery

  

0.144

 Every 3 weeks(80–100 mg/m2)

39 (62.9%)

64 (51.6%)

 

 Weekly (30–40 mg/m2)

23 (37.1%)

60 (48.4%)

 

EBV DNA level

  

1

  < 4000 copies

35 (56.5%)

70 (56.5%)

 

  ≥ 4000 copies

27 (43.5%)

54 (43.5%)

 

VCA-IgA

  

1

  < 1:80

15 (24.2%)

30 (24.2%)

 

  ≥ 1:80

47 (75.8%)

94 (75.8%)

 

EA-IgA

  

0.148

  < 1:10

24 (38.7%)

35 (28.2%)

 

  ≥ 1:10

38 (61.3%)

89 (71.8%)

 

ECOG

  

1

 0

1 (1.6%)

2 (1.6%)

 

 1

61 (98.4%)

122 (98.4%)

 

LDH,U/L

  

0.666

  < 245

61 (98.4%)

120 (96.8%)

 

  ≥ 245

1 (1.6%)

4 (3.2%)

 

CRP,g/ml

  

0.286

  < 3.00

49 (79.0%)

89 (71.8%)

 

  ≥ 3.00

13 (21.0%)

35 (28.2%)

 

Body mass index, kg/m2

  

1

  < 18.5

3 (4.8%)

5 (4.0%)

 

  ≥ 18.5

59 (95.2%)

119 (96.0%)

 

Smoking

  

0.46

 Yes

20 (32.2%)

59 (47.6%)

 

 No

42 (67.7%)

65 (52.4%)

 

Family history of cancer

  

0.02

 Yes

13 (21.0%)

11 (8.9%)

 

 No

49 (79.0%)

113 (91.1%)

 
  1. Abbreviations: CCRT concurrent chemoradiotherapy, WHO World Health Organization, 2DRT two-dimensional radiotherapy, IMRT intensity-modulated radiotherapy, EA early antigen, VCA viral capsid antigen, IgA immunoglobulin A, EBV DNA Epstein-Barr virus DNA, ECOG Eastern Cooperative Oncology Group, CRP C-reactive protein, LDH serum lactate dehydrogenase levels